Detalles de la búsqueda
1.
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 20(1): 126-135, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33039584
2.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 18(13): 2952-2961.e8, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32062041
3.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 17(12): 2497-2505.e1, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30625408
4.
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Aliment Pharmacol Ther
; 52(4): 669-681, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656800
5.
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
Inflamm Bowel Dis
; 25(11): 1854-1861, 2019 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31050734
Resultados
1 -
5
de 5
1
Próxima >
>>